Drug Name: | Exemestane (107868-30-4) |
---|---|
PubChem ID: | 60198 |
SMILES: | C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C |
InchiKey: | BFYIZQONLCFLEV-DAELLWKTSA-N |
Therapeutic Category: | Antineoplastic Agents, Aromatase Inhibitors, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormones |
Molecular Weight (dalton) | : | 296.41 |
LogP | : | 4.0295 |
Ring Count | : | 0 |
Hydrogen Bond Acceptor Count | : | 2 |
Hydrogen Bond Donor Count | : | 0 |
Total Polar Surface Area | : | 34.14 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Cardiovascular Disease | Adenylate kinase (P00568) | Total suppression of aromatase by exemestane may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
Depression | Alpha-1A adrenergic receptor (P35348) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets |
Oedema | Beta-2 adrenergic receptor (P07550) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets |
Osteoporosis | Adenylate kinase (P00568) | Total suppression of aromatase by exemestane may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
Urogenital Atrophy | Adenylate kinase (P00568) | Total suppression of aromatase by exemestane may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category